Ana Oaknin, MD

Ana Oaknin, MD, head of the Gynecologic Tumors Unit, Vall d&rsquo;Hebron University Hospital, and principal investigator, Gynecological Malignancies Group, explains the rationale for analyzing antiPD-1 monotherapy with&nbsp;dostarlimab(TSR-042) in patients with microsatellite instability&ndash;high (MSI-H) and microsatellite stable (MSS) endometrial cancer.&nbsp;

With limited options available for treating women with advanced or recurrent endometrial cancer, the phase I/II&nbsp;

analyzed 125 patients33% with MSI-H endometrial cancer, 63% with MSS disease, and the remaining with unknown MSI status&mdash;receiving treatment with dostarlimab 500 mg in 4 doses every 3 weeks. Patients then received 1000 mg of the antiPD-1 monotherapy every 6 weeks until disease progression. The study found clinically relevant overall response rates (ORRs). The full population showed a 30% ORR, MSI-H patients had a 49% ORR, and MSS patients had a 20% ORR.

The purpose for this study was to look at antiPD-1 monotherapy across multiple patient populations for endometrial cancer, says Oaknin. It addresses the limitations with standard therapies and the need for a therapy that targets MSS, unlike the commonly used treatment, pembrolizumab (Keytruda), which was approved specifically for the treatment of patients with MSI-H endometrial cancer.

Videos

Ana Oaknin, MD, head of the Gynecologic Tumors Unit, Vall d&rsquo;Hebron University Hospital,&nbsp;and principal investigator, Gynecological Malignancies Group, explains the rationale for analyzing anti&ndash;PD-1 monotherapy with&nbsp;dostarlimab in patients with microsatellite instability&ndash;high and microsatellite stable endometrial cancer.&nbsp;

Ana Oaknin, MD | Authors

Articles

The Rationale for Dostarlimab Monotherapy In MSI-H and MSS Endometrial Cancer